Skip to main content

Michael Daniel

Nov 20, 2026

18:05
Absolutely.
18:06
And in the case of OPM, that was really about straight up espionage.
18:13
But what made that case so interesting was it was on a scale and a scope that we really hadn't seen before in terms of people's personal data.
18:24
And so what was also interesting about that one was we learned about it because OPM was trying to do the right thing.
18:32
So the Office of Personnel Management is the part of the U.S. government that is like the HR department for the U.S. government as a whole, right? One of the things that it does is it maintains the personnel records of a lot of U.S.
18:51
government employees, including if they have clearances and all of the paperwork that goes along with these clearances.
19:01
And OPM is not known as being a forward-leaning agency, typically.

19 MINS LATER

38:04
Talk to us a bit about quantum AI and where you see the greatest opportunities and threats are emerging.
23:54
many leaders we've spoken to they describe a choice between moving too slowly and leaving critical systems exposed or moving too quickly and disrupting operations right from your time in government michael and with critical infrastructure in general how do you think about that trade-off and what separates a rushed fix from a well-managed one
24:16
yeah it's you know um I think it is one of those things that there is some judgment involved, right? And it's difficult to give a hard and fast rule.
24:28
Einstein said, your theory should be as simple as possible, but no simpler, right? I would say that the key in my mind is you should be moving as fast as you can actually make the informed decisions.
24:50
And this is always a challenge because you will always lack some information, particularly in government.
24:58
You're always making decisions under uncertainty.
25:02
And so the real judgment is, for a leader, in my view, is knowing when you've reached the limits of what more information gathering, more options will do for you, because then you're just avoiding the decision.
25:21
And that's a natural human tendency.

5 MINS LATER

30:45
In what way is the sort of AI making organizations safer and more capable? And where is it creating new fragilities, blind spots, and attack surfaces? And to what degree do those two amplifications balance one another out, I guess? Yeah.
AmakriHOST
3:08
Go ahead.
3:12
I want to write a book so that I can inspire young children with my books.
AmakriHOST
3:44
What does it mean to publish?
3:47
Uh, to design the book and make it presentable for others to read.
14:44
From that vantage point, what's the role of government versus private sector and cybersecurity? Who actually owns cybersecurity today?
14:55
Well, it's an interesting question because I think that actually part of our problem is that there are two sides to cybersecurity, right? One of them is there is actually a private part of cybersecurity.
15:11
In other words, you want to have cybersecurity for yourself because it's to your benefit, right? You don't want to lose your money online.
15:21
You want to keep your business functioning.
15:23
You... you know, whatever the reasons, you have a private interest in cybersecurity.
15:32
However, because we're all networked, right? And this thing called the internet connects all of us and connects our systems together.
15:45
Your risk is also my risk and my risk is also your risk.

12 MINS LATER

28:00
How do you walk into a boardroom and shake the CEO and board members and ask the question, are we defending companies or are we defending systems that sustain the
5:04
Now, we'd anticipated that small molecule oncology would be the area that would have a high exposure to IRA, Were you surprised at Sanofi with those results? Is that what you were anticipating when you asked us to do this work?
5:16
You know, it's interesting because we had suspicions.
5:19
We wanted to understand the impact of what we call the pill penalty or the disadvantaging of the small molecules in terms of drug selection for Medicare negotiation.
5:29
as compared to their biological brethren.
5:32
The issue was we wanted to get some level of evidence to help validate our suspicions.
5:38
And I think that this particular study and this research to understand not just the impact on small molecule investment and innovation, but then also all the work that you guys have done to look at all the post-market impact that I think is very, very important because much of the innovation comes from the life cycle of the medicine, even after it gets to market, which is really, really important, especially in orphan drugs or rare diseases or oncology in particular.
6:07
We wanted to kind of bring this to ASCO.

19 MINS LATER

25:30
Where do you think we're going to be in three to five years right now?
11:38
Certainly nobody at the size of the members of the CTA, right?
11:43
Right.
11:44
And so instead, what you're really competing on is what you do with the threat intelligence, right? You are competing on the basis of my technology is better, my customer service is better, my understanding of your industry is better, right? And so when you look at it that way, if you have access to more knowledge, right, and you're using that knowledge to fuel your protections, to fuel your customer service, to fuel your knowledge of an industry, having more of that knowledge makes you more competitive.
12:18
Yes, at the same time, it also helps the ecosystem and your competitor.
12:24
But at one level, what I say is we're actually raising the competition up off of what we know, which is kind of the base level, up higher in the value chain.
12:34
So that's actually better off for companies because you're more competitive.
12:38
It's better off for the ecosystem because that competition is happening at a higher level.

6 MINS LATER

18:55
Do you want to just describe that briefly? Because I really was a fan of it.
97:52
Can you speak to what's happening here in that announcement?
97:55
Well, first of all, I'm glad you brought up the, uh, the fitness, uh, videos that they were doing with RFK Jr and Hesketh.
98:01
I mean, it's great to see, you know, people working out and exercising, but it's a good reminder that just because you can do a hundred pull-ups or a hundred pushups doesn't necessarily mean that you can make the best medical recommendations for our country.
98:15
So let's just get that right out there.
98:17
So the big breaking news, as you mentioned for the, this is the first time in three decades, I heard that the American Academy of Pediatrics is going against the CDC recommendation on a vaccine.
98:31
And it's for the COVID vaccine.
98:32
And the recommendation is for infants from six months to two years.

6 MINS LATER

104:49
Flumist, is that what it's called? It's an at-home nasal vaccine.
89:44
Tell me how much of that statement and how much of that idea that I've just proffered is true.
89:50
Right.
89:50
So I think you're reflecting a lot of the general sentiment, but I think the issue is much more complicated and it's drug by drug, vaccine by vaccine specific, right? So if you look at the COVID vaccines in particular, they were funded by U.S.
90:05
government funding, right? And that's our taxpayer dollars.
90:08
And that was Operation Warp Speed by President Trump, who I mean, again, I've said this before.
90:15
It's amazing that he doesn't talk about this as much anymore because it was such a remarkable scientific achievement to come up with multiple vaccines against a pandemic in a matter of nine months.
90:28
Like total game changer.

5 MINS LATER

95:56
What do we know about the new CDC director?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.